ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge

At ACR: Janssen reported data that show Celltrion’s Remicade biosimilar is not quite the same, but positive sirukumab results may not boost the Janssen and GSK biologic’s market prospects. Meanwhile, Corbus surged on mid-stage resunab results in systemic sclerosis, Janssen shared Phase II gesulkumab psoriasis results, Genentech eyes a new Actemra indication, and Xencor rose on interim Phase II data.

Drug efficacy was reported across a variety of inflammatory diseases during the American College of Rheumatology (ACR) Annual Meeting from Nov. 11 to 16 in Washington, D.C., but Johnson & Johnson’s Janssen Biotech Inc. shared data that show Celltrion Inc.’s Remicade (infliximab) biosimilar may not be equivalent to the name-brand biologic in the treatment of rheumatoid arthritis (RA).

Janssen also showcased Phase III results alongside partner GlaxoSmithKline PLC for the Interleukin-6 (IL-6) inhibitor sirukumab, but the data...